Below are the financial statements of SCHOTT Pharma AG & Co, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of EUR | 2024 2023-10-01 - 2024-09-30 | 2023 |
|---|---|---|
| Revenue | 957.09a | 898.6a |
| Cost of sales | -634.48a | -582.11a |
| Gross profit | 322.61a | 316.49a |
| Selling expenses | -79.84a | -79.16a |
| General administrative expenses | -44.63a | -42.93a |
| Research and development costs | -24.25a | -26.82a |
| Other operating income | 26.4a | 25.74a |
| Other operating expenses | -20.19a | -12.68a |
| Share of profit from investments accounted for using the equity method | 12.49a | 11.74a |
| Operating income (EBIT) | 192.58a | 192.38a |
| Interest income | 5.96a | 5.23a |
| Interest expenses | -13.49a | -7.25a |
| Net other financial result | -1.08a | -4.55a |
| Financial result | -8.61a | -6.58a |
| Profit before income taxes | 183.97a | 185.8a |
| Income tax expenses | -33.63a | -33.87a |
| Profit for the period | 150.35a | 151.93a |
| Thereof attributable to non-controlling interests | 0.66a | 0.09a |
| Thereof attributable to limited liability shareholders of SCHOTT Pharma AG & Co. KGaA | 149.69a | 151.84a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.